Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, attributed to positive developments in its financial and clinical research activities [1] Financial Developments - 加科思's subsidiary, 北京加科思, has received an initial payment of RMB 125 million from 海松资本, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the group's innovative oncology therapy pipeline [1] Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]
港股异动 加科思-B(01167)盘中涨超6% 附属收到1.25亿元首付款 联合疗法登上《柳叶刀》